Global Bio CMO Market: Size & Forecasts with Impact Analysis of Covid-19 (2020-2024 Edition)
Scope of the Report
The report entitled “Global Bio CMO Market: Size & Forecasts with Impact Analysis of Covid-19 (2020-2024 Edition)”, provides analysis of the global bio CMO market, with detailed analysis of market size and growth, penetration rate, and manufacturing process. A brief segment analysis is provided with their actual and forecasted value. In addition, an analysis of the global biologics market by value, by top selling products, etc. is also mentioned in the report.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global bio CMO has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Lonza Group, Boehringer Ingelheim, Samsung Biologics and Wuxi Biologics are key companies in the global bio CMO market. The company profiling of these companies has been done in the report, which includes business overview, financial overview and respective business strategies of the companies.
Company Coverage
The global bio CMO market has witnessed stable growth in the past few years and is expected to grow at a healthy rate during the forecasted period (2020-2024), the market is anticipated to further propel with a poised growth rate. The growth of global bio CMO market would be supported by the growth drivers such as rising pharmaceutical industry, growth in biosimilar industry, rise in drug approvals etc. However, the growth of global bio CMO market is being obstructed by numerous challenges such as, lack of technology, security and knowledge, inappropriate methods followed by CMOs etc.
It is being seen that many CMOs are now interested to differentiate their services. For this purpose, many CMOs are actively endorsing their integrated development and manufacturing services. Hence, they are preferring to be known as CDMOs. In the wake of Covid-19, CDMOs are actively engaged in the process of developing therapeutics and vaccines for the ongoing pandemic.
The report entitled “Global Bio CMO Market: Size & Forecasts with Impact Analysis of Covid-19 (2020-2024 Edition)”, provides analysis of the global bio CMO market, with detailed analysis of market size and growth, penetration rate, and manufacturing process. A brief segment analysis is provided with their actual and forecasted value. In addition, an analysis of the global biologics market by value, by top selling products, etc. is also mentioned in the report.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global bio CMO has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Lonza Group, Boehringer Ingelheim, Samsung Biologics and Wuxi Biologics are key companies in the global bio CMO market. The company profiling of these companies has been done in the report, which includes business overview, financial overview and respective business strategies of the companies.
Company Coverage
- Lonza Group
- Boehringer Ingelheim
- Samsung Biologics
- Wuxi Biologics
The global bio CMO market has witnessed stable growth in the past few years and is expected to grow at a healthy rate during the forecasted period (2020-2024), the market is anticipated to further propel with a poised growth rate. The growth of global bio CMO market would be supported by the growth drivers such as rising pharmaceutical industry, growth in biosimilar industry, rise in drug approvals etc. However, the growth of global bio CMO market is being obstructed by numerous challenges such as, lack of technology, security and knowledge, inappropriate methods followed by CMOs etc.
It is being seen that many CMOs are now interested to differentiate their services. For this purpose, many CMOs are actively endorsing their integrated development and manufacturing services. Hence, they are preferring to be known as CDMOs. In the wake of Covid-19, CDMOs are actively engaged in the process of developing therapeutics and vaccines for the ongoing pandemic.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Pharmaceutical Industry Overview
2.1.1 Segments of Pharmaceutical Industry (Drugs)
2.2 Biotechnology/Biologics Overview
2.3 Biosimilar Overview
2.4 Biologics/ Biosimilar Manufacturing
2.5 Bio CMO Overview
2.5.1 Comparison: In-House Vs CMO Production
3. GLOBAL MARKET ANALYSIS
3.1 Global Biologics Market Analysis
3.1.1 Global Biologics Market by Value
3.1.2 Global Biologics Market by Top Selling Drugs
3.2 Global Biologics Manufacturing Market Analysis
3.2.1 Global Biologics Manufacturing Market by Value
3.2.2 Global Biologics Manufacturing Market by Segments
3.3 Global Bio CMO Market Analysis
3.3.1 Global Bio CMO Market by Value
3.3.2 Global Bio CMO Market by Penetration Rate
3.3.3 Global Bio CMO Market by Manufacturing Processes
3.4 Global Bio CMO Market Segment Analysis
3.4.1 Global Bio CMO Downstream Process Market by Value
3.4.2 Global Bio CMO Upstream Process Market by Value
3.4.3 Global Bio CMO Fill and Finish Process Market by Value
4. IMPACT OF COVID-19
4.1 Impact on Global Bio CMO Market
4.1.1 CMO Market and Covid-19
4.1.2 Participation of CDMOs in Covid-19 Vaccine Development Projects
4.1.3 CDMOs Planning for Fill and Finish Manufacture of Covid-19 Vaccine
4.1.4 Challenges
5. MARKET DYNAMICS
5.1 Growth Drivers
5.1.1 Rising Pharmaceuticals Industry
5.1.2 Surging Geriatric Population
5.1.3 Growth in Biosimilar Industry
5.1.4 Preference of Biologics Over Small Molecules
5.2 Challenges
5.2.1 Lack of Technology, Security and Knowledge
5.2.2 Inappropriate Methods Followed by CMOs
5.3 Market Trends
5.3.1 Surging Pharmaceuticals Outsourcing Rate
5.3.2 Capacity Utilization Rate of CMO Industry
5.3.3 Augmenting Need for Dual Sourcing
5.3.4 Growth in Mammalian Cell Structure
6. COMPETITIVE LANDSCAPE
6.1 Global Bio CMO Market Players: A Financial Comparison
6.2 Global Biologics Outsourcing Market Share by Players
7. COMPANY PROFILES
7.1 Lonza
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 Boehringer Ingelheim
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Samsung Electronics (Samsung Biologics)
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Wuxi Biologics
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
2. INTRODUCTION
2.1 Pharmaceutical Industry Overview
2.1.1 Segments of Pharmaceutical Industry (Drugs)
2.2 Biotechnology/Biologics Overview
2.3 Biosimilar Overview
2.4 Biologics/ Biosimilar Manufacturing
2.5 Bio CMO Overview
2.5.1 Comparison: In-House Vs CMO Production
3. GLOBAL MARKET ANALYSIS
3.1 Global Biologics Market Analysis
3.1.1 Global Biologics Market by Value
3.1.2 Global Biologics Market by Top Selling Drugs
3.2 Global Biologics Manufacturing Market Analysis
3.2.1 Global Biologics Manufacturing Market by Value
3.2.2 Global Biologics Manufacturing Market by Segments
3.3 Global Bio CMO Market Analysis
3.3.1 Global Bio CMO Market by Value
3.3.2 Global Bio CMO Market by Penetration Rate
3.3.3 Global Bio CMO Market by Manufacturing Processes
3.4 Global Bio CMO Market Segment Analysis
3.4.1 Global Bio CMO Downstream Process Market by Value
3.4.2 Global Bio CMO Upstream Process Market by Value
3.4.3 Global Bio CMO Fill and Finish Process Market by Value
4. IMPACT OF COVID-19
4.1 Impact on Global Bio CMO Market
4.1.1 CMO Market and Covid-19
4.1.2 Participation of CDMOs in Covid-19 Vaccine Development Projects
4.1.3 CDMOs Planning for Fill and Finish Manufacture of Covid-19 Vaccine
4.1.4 Challenges
5. MARKET DYNAMICS
5.1 Growth Drivers
5.1.1 Rising Pharmaceuticals Industry
5.1.2 Surging Geriatric Population
5.1.3 Growth in Biosimilar Industry
5.1.4 Preference of Biologics Over Small Molecules
5.2 Challenges
5.2.1 Lack of Technology, Security and Knowledge
5.2.2 Inappropriate Methods Followed by CMOs
5.3 Market Trends
5.3.1 Surging Pharmaceuticals Outsourcing Rate
5.3.2 Capacity Utilization Rate of CMO Industry
5.3.3 Augmenting Need for Dual Sourcing
5.3.4 Growth in Mammalian Cell Structure
6. COMPETITIVE LANDSCAPE
6.1 Global Bio CMO Market Players: A Financial Comparison
6.2 Global Biologics Outsourcing Market Share by Players
7. COMPANY PROFILES
7.1 Lonza
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 Boehringer Ingelheim
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Samsung Electronics (Samsung Biologics)
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Wuxi Biologics
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
LIST OF FIGURES
Figure 1: History of Pharmaceutical Industry
Figure 2: Pharmaceutical Industry Segments
Figure 3: Global Biologics Market by Value; 2016-2019 (US$ Billion)
Figure 4: Global Biologics Market by Value; 2020-2024 (US$ Billion)
Figure 5: Global Biologics Manufacturing Market by Value; 2015-2019 (US$ Billion)
Figure 6: Global Biologics Manufacturing Market by Value; 2020-2024 (US$ Billion)
Figure 7: Global Biologics Manufacturing Market by Segments; 2019 (Percentage, %)
Figure 8: Global Bio CMO Market by Value; 2015-2019 (US$ Billion)
Figure 9: Global Bio CMO Market by Value; 2020-2024 (US$ Billion)
Figure 10: Global Bio CMO Market by Penetration Rate; 2014-2018 (Percentage, %)
Figure 11: Global Bio CMO Market by Penetration Rate; 2019-2023 (Percentage, %)
Figure 12: Global Bio CMO Market by Manufacturing Processes; 2019 (Percentage, %)
Figure 13: Global Bio CMO Downstream Process Market by Value; 2015-2019 (US$ Billion)
Figure 14: Global Bio CMO Upstream Process Market by Value; 2015-2019 (US$ Billion)
Figure 15: Global Bio CMO Fill and Finish Process Market by Value; 2015-2019 (US$ Billion)
Figure 16: Global Pharmaceuticals Market Value; 2018-2023 (US$ Trillion)
Figure 17: Global Ageing Population; 2017-2050 (Million)
Figure 18: Global Biosimilar Market Value; 2018-2023 (US$ Billion)
Figure 19: Global Biopharmaceuticals (Drugs) Market by Segments; 2015-2022 (Percentage, %)
Figure 20: Big Pharmaceuticals Outsourcing Rate; 2015-2020 (Percentage, %)
Figure 21: Capacity Utilization Rate of the Global CMO Industry; 2014-2020 (Percentage, %)
Figure 22: Global Biologics Outsourcing Market Share by Players; 2018 (Percentage, %)
Figure 23: Lonza Group Sales; 2015-2019 (US$ Billion)
Figure 24: Lonza Group Sales by Region; 2019
Figure 25: Lonza Group Sales by Segments; 2019
Figure 26: Boehringer Ingelheim Sales; 2015-2019 (US$ Billion)
Figure 27: Boehringer Ingelheim Sales by Segments; 2019
Figure 28: Boehringer Ingelheim Sales by Region; 2019
Figure 29: Samsung Electronics Segments Overview
Figure 30: Samsung Electronics Ownership Structure
Figure 31: Samsung Electronics and Biologics Revenue; 2015-2019 (US$ Billion)
Figure 32: Wuxi Biologics Revenue; 2015-2019 (US$ Million)
Figure 33: Wuxi Biologics Revenue by Services; 2018
Figure 34: Wuxi Biologics Revenue by Region; 2019
Table 1: Chemical Drugs v/s 1st Generation Biologics v/s 2nd Generation Biologics
Table 2: US Approved Biosimilars
Table 3: Comparison: In-House Vs CMO Production
Table 4: Top Selling Biologic Drugs; 2019
Table 5: Global Bio CMO Market Players: A Financial Comparison; 2019
Figure 1: History of Pharmaceutical Industry
Figure 2: Pharmaceutical Industry Segments
Figure 3: Global Biologics Market by Value; 2016-2019 (US$ Billion)
Figure 4: Global Biologics Market by Value; 2020-2024 (US$ Billion)
Figure 5: Global Biologics Manufacturing Market by Value; 2015-2019 (US$ Billion)
Figure 6: Global Biologics Manufacturing Market by Value; 2020-2024 (US$ Billion)
Figure 7: Global Biologics Manufacturing Market by Segments; 2019 (Percentage, %)
Figure 8: Global Bio CMO Market by Value; 2015-2019 (US$ Billion)
Figure 9: Global Bio CMO Market by Value; 2020-2024 (US$ Billion)
Figure 10: Global Bio CMO Market by Penetration Rate; 2014-2018 (Percentage, %)
Figure 11: Global Bio CMO Market by Penetration Rate; 2019-2023 (Percentage, %)
Figure 12: Global Bio CMO Market by Manufacturing Processes; 2019 (Percentage, %)
Figure 13: Global Bio CMO Downstream Process Market by Value; 2015-2019 (US$ Billion)
Figure 14: Global Bio CMO Upstream Process Market by Value; 2015-2019 (US$ Billion)
Figure 15: Global Bio CMO Fill and Finish Process Market by Value; 2015-2019 (US$ Billion)
Figure 16: Global Pharmaceuticals Market Value; 2018-2023 (US$ Trillion)
Figure 17: Global Ageing Population; 2017-2050 (Million)
Figure 18: Global Biosimilar Market Value; 2018-2023 (US$ Billion)
Figure 19: Global Biopharmaceuticals (Drugs) Market by Segments; 2015-2022 (Percentage, %)
Figure 20: Big Pharmaceuticals Outsourcing Rate; 2015-2020 (Percentage, %)
Figure 21: Capacity Utilization Rate of the Global CMO Industry; 2014-2020 (Percentage, %)
Figure 22: Global Biologics Outsourcing Market Share by Players; 2018 (Percentage, %)
Figure 23: Lonza Group Sales; 2015-2019 (US$ Billion)
Figure 24: Lonza Group Sales by Region; 2019
Figure 25: Lonza Group Sales by Segments; 2019
Figure 26: Boehringer Ingelheim Sales; 2015-2019 (US$ Billion)
Figure 27: Boehringer Ingelheim Sales by Segments; 2019
Figure 28: Boehringer Ingelheim Sales by Region; 2019
Figure 29: Samsung Electronics Segments Overview
Figure 30: Samsung Electronics Ownership Structure
Figure 31: Samsung Electronics and Biologics Revenue; 2015-2019 (US$ Billion)
Figure 32: Wuxi Biologics Revenue; 2015-2019 (US$ Million)
Figure 33: Wuxi Biologics Revenue by Services; 2018
Figure 34: Wuxi Biologics Revenue by Region; 2019
Table 1: Chemical Drugs v/s 1st Generation Biologics v/s 2nd Generation Biologics
Table 2: US Approved Biosimilars
Table 3: Comparison: In-House Vs CMO Production
Table 4: Top Selling Biologic Drugs; 2019
Table 5: Global Bio CMO Market Players: A Financial Comparison; 2019
